TetraDerm Cohort 1 Results
Filed with ASX · · 5 pages · English
Tetratherix Limited (ASX: TTX) (Tetratherix) is pleased to announce the interim performance results from the clinical use of its scar prevention product (TetraDerm) on patients undergoing surgeries to remove skin lesions that created incisions up to 9cm in length. Interim results from Cohort 1 of the TetraDerm study show that when the product is laid between layers of skin tissue before final woun
Story so far
Earlier from Tetratherix
- Quarterly Activities/Appendix 4C Cash Flow Report
- Executed Henry Schein Agreement
- TetraDerm Cohort 2
- Q1FY26 Quarterly Activities Report/Appendix 4C
- 2025 Financial Results Investor Presentation
Later from Tetratherix
- Half Yearly Report and Accounts
- Tutelix Update
- Precision medicine franchise launch and new revenue
- Successful Completion $15M Placement
- Appendix 4E and Annual Report 2026
Follow Tetratherix into a list and get an email when it puts out news.
Follow Tetratherix